Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010 by Zhu, Hao et al.
Attrition among Human Immunodeficiency Virus (HIV)-
Infected Patients Initiating Antiretroviral Therapy in
China, 2003–2010
Hao Zhu
1,3, Sonia Napravnik
1,2, Joseph Eron
1,2, Stephen Cole
1,Y eM a
3, David Wohl
2, Zhihui Dou
3,
Yao Zhang
3, Zhongfu Liu
3, Decai Zhao
3, Myron Cohen
1,2*
., Fujie Zhang
3,4*
.
1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina, United States of America, 2Division of
Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, North Carolina, United States of America, 3National Center for AIDS/STD Control and
Prevention, Chinese Center for Disease Control and Prevention, Beijing, China, 4Beijing Ditan Hospital Capital Medical University, Beijing, China
Abstract
Background: Mortality and morbidity from HIV have dramatically decreased in both high- and low-income countries.
However, some patients may not benefit from combination antiretroviral therapy (cART) because of inadequate access to
HIV care, including attrition after care initiation.
Methodology/Principal Findings: The study population included all HIV-infected patients receiving cART through the
Chinese National Free Antiretroviral Treatment Program from 1 January 2003 to 31 December 2010 (n=106,542). We
evaluated retention in HIV care and used multivariable Cox proportional hazard models to identify independent factors
predictive of attrition. The cumulative probability of attrition from cART initiation was 9% at 12 months, 13% at 18 months,
16% at 24 months and 24% at 60 months. A number of factors were associated with attrition, including younger age, male
gender, and being single or divorced. Patients with higher CD4 cell counts at cART initiation were more likely to drop out of
HIV care. The proportion of patients remaining in HIV care increased in more recent calendar years and among patients who
initiated modern cART regimens.
Conclusions/Significance: Retention in HIV care is essential for optimizing individual and public health outcomes. Attrition,
even the degree observed in our study, can lead to premature morbidity and mortality, and possibly affect further
transmission of HIV and HIV resistant drug variants. Effective strategies to promote retention in HIV care programs are
needed. In China these strategies may include focusing particularly on younger male patients and those with higher CD4
cell counts at therapy initiation.
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Introduction
Local, national and international efforts have strived to make
combination antiretroviral therapy (cART) available to patients
with human immunodeficiency virus (HIV) around the globe,
including China [1,2,3]. With these efforts and the increasing
effectiveness of provided cART, mortality and morbidity from
HIV have dramatically decreased in high- and low-income areas
of the world [4,5,6]. However, some patients may not benefit from
cART because of inadequate access to HIV care, including
attrition after care initiation [7,8,9]. Estimates of attrition depend
in large part on the definition of attrition used, the location and
nature of the study population, and other study characteristics
[10,11,12,13].
Among HIV-infected patients initiating cART living in high-
income areas of the world, attrition rates can be as low as 5%
during the first year of treatment [5]. Studies conducted among
patients living in low-income areas of the world have observed up
to 50% attrition to HIV care, with many of these patients not
returning to care because of death [14]. Better understanding of
attrition among HIV-infected patients in care is essential to
evaluating HIV clinical care provision and informing interventions
for improving retention in care [15]. Retention in care could help
improve individual clinical outcomes [16] and reduce risk of
further HIV transmission in the community [17].
There were an estimated 740,000 HIV-infected patients living
in China as of 2009 [18]. The major routes of HIV transmission in
China include injection drug use (IDU), blood transfusion/former
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free cART provision through the National Free Antiretroviral
Treatment Program (NFATP) in 2002. As of the end of 2009, over
80,000 HIV-infected patients had received cART through
NFATP [4]. The effectiveness of this program in reducing
mortality has been described previously [20,21]. However, little
is known about retention in HIV care among HIV-infected
patients in China. The purpose of this study was to describe
temporal trends in attrition and identify factors associated with
greater risk of attrition among patients receiving cART through
the Chinese NFATP Program from 2003 to 2010.
Methods
Study Population
The study population included all HIV-infected patients
receiving cART through the Chinese NFATP from 1 January
2003 to 31 December 2010 (n=106,542). The NFATP is
managed by the Division of Treatment and Care in the National
Center for AIDS/STD Control and Prevention, Chinese Center
for Disease Control and Prevention. Detailed descriptions relevant
to the management, process and methods of the Chinese NFATP
have been published [22,23]. The program used standardized
paper based case report forms which were completed by local
health workers and then faxed to a central office in the Division of
Treatment and Care [24]. In 2010, a web-enabled electronic data
collection system was implemented. At the visit when patients start
cART, a standardized form for initial patient assessment is
completed and baseline information is collected, including
demographic data, suspected HIV infection exposure route,
clinical symptoms and signs, and laboratory test results. Subse-
quent follow up visits are scheduled for 2, 4, 8 and 12 weeks
following cART initiation, and then every 3 months thereafter.
Patients who transfer to another NFATP clinical site retain the
same patient identification number that is assigned at cART
initiation and therefore patients can be tracked centrally across
NFATP clinical sites. Information on death, including reason and
date of death, was available through the NFATP treatment
withdrawal forms. These forms were also completed by local
health workers and sent to central NFATP offices.
From its inception, NFATP provided free cART to all HIV-
infected patients with a CD4 cell counts below 200 cells/mL, a
total lymphocyte counts ,1200 cells/mL or a World Health
Organization (WHO) stage III or IV. At the beginning of 2008,
patients with CD4 cell counts ,350 cells/mL became eligible for
free cART in accordance with updated WHO guidelines [24].
For these analyses we included all HIV-infected adults who
were ART-naı ¨ve at the time they initiated free cART through
NFATP. Henan Province did not submit data to NFATP until July
1, 2006; therefore, patients residing in Henan Province who
initiated cART before that date were excluded from this analysis
(n=16,609) [25]. Additionally we excluded patients who did not
have any recorded follow-up (n=2,896), consistent with prior
work in this area [26], and those who initiated cART less than 210
days (approximately seven months) prior to 31 December 2010 to
allow for adequate follow-up (n=14,195).
The data were analyzed anonymously. This study was approved
by the Institutional Review Board at the University of North
Carolina at Chapel Hill. Individual informed consent was not
needed because this analysis used currently existing data collected
during the course of routine treatment and care.
Measurements
Attrition was defined as not having a visit for at least 210 days.
This is approximately seven months, which allows leniency for
those who miss a standard three-month NFATP visit but are seen
within four weeks of the following scheduled NFATP visit.
Moreover, this seven month definition is roughly similar to the
definition of six months used in prior studies [27,28]. In sensitivity
analyses, we assessed the effect of using different time intervals to
define attrition, including 180, 270 and 360 days from last
observation. Factors measured at baseline included age, gender,
marital status, suspected HIV exposure route, initial cART
regimen, CD4 cell counts, alanine aminotransferase and hemo-
globin at cART initiation. Baseline symptoms recorded include
fever, cough, sputum production, dyspnea, chest pain, night sweat,
diarrhea, nausea, projectile vomiting, headache, declining vision,
blurred vision, rash, thrush, oral hairy leukoplakia, and lymph-
adenopathy. For these analyses, we summed the number of
symptoms reported for each patient as a measure of clinical
symptom severity. Antiretroviral therapy regimens were catego-
rized as: neviripine (NVP) with lamivudine (3TC) and either
zidovudine (AZT) or stavudine (D4T); efavirenz (EFV) with 3TC
and either AZT or D4T; NVP and didanosine (DDI) and either
AZT or D4T; and all other regimens. Health care setting (general
hospital, infectious diseases hospital, centers for diseases control
clinic, health care center at township level, village clinic and prison
hospital), area of residence (eastern, central and western region)
and calendar year of cART initiation were also included.
Statistical Analysis
Person-time was calculated as time from cART initiation to the
first of attrition or date of censoring. Patients were censored at the
date of death or 31 December 2010, whichever occurred first. The
complement of the Kaplan-Meier survival curve was used to plot
the cumulative incidence of attrition by levels of factors of interest.
The log-rank test statistic was used to assess differences in survival
curves.
Cox proportional hazard models were used to estimate
unadjusted and adjusted hazard ratios and 95% confidence
intervals (CI), and we assessed for deviations from the proportional
hazard assumption. Based on the bivariable results, we identified
factors predictive of the outcome with a P value,0.2. These
factors were jointly entered into a model. Then backward
elimination was used to sequentially remove covariates with the
highest P-values such that the final model included only factors
predictive of the outcome defined as a P value,0.05.
Given the relationship between type of antiretroviral therapy
available through NFATP and calendar year of starting cART, we
explored the relationship between type of therapy and attrition in
models stratified by calendar year of cART initiation. As a
sensitivity analysis we administratively censored follow-up time at
12 and 24 months following cART initiation rather than at 31
December 2010. We also performed sensitivity analyses to assess
whether results were robust to excluding patients with no follow-
up. Data were analyzed using SAS version 9.2 (SAS Institute, Cary
NC, USA). All hypothesis testing was 2-sided, with a level of 0.05.
Results
Between 1 January 2003 and 31 May 2010, 67,732 HIV-
infected patients who initiated cART through the Chinese NFATP
were included in this analysis. Over one-third (37%) of patients
were women, 51% were infected through heterosexual contact,
23% through blood transfusion/former plasma donation, and
22% through IDU (Table S1). At cART initiation, the median age
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CD4 cell counts was 131 cells/mL (IQR: 42–220). The median
year of cART initiation was 2008 (IQR: 2007–2009). The initial
cART regimen prescribed was predominantly NVP and 3TC with
either AZT or D4T (70%).
Patients contributed a median of 20 months of follow-up (IQR:
11–34) and 8 visits (IQR: 5–13) from cART initiation to first
attrition event, death or censoring. The overall person-time
contributed was 137,792 person-years. Of the 67,732 HIV-
infected patients, 9,969 were lost to HIV care, and the remaining
57,763 were administratively censored (7,390 of these 57,763 were
censored at death). Among those administratively censored the
median time on study was 22 months (IQR: 13–37), and among
those who died the median time to death was 4 months (IQR: 1–
11). The cumulative probability of attrition from cART initiation
was 9% at 12 months, 13% at 18 months, 16% at 24 months and
24% at 60 months (Figure 1).
A number of factors were associated with attrition in unadjusted
and adjusted analyses, including younger age, male gender and
being single or divorced (Table S2). Patients infected through IDU
were almost twice as likely to be lost to HIV care as those infected
by heterosexual contact [adjusted Hazard Ratio (aHR) 1.87, 95%
CI: 1.76, 1.98] (Table S2, Figure 2A). Patients initiating cART in
the central region of China were less likely to be lost to HIV care
than patients living in other areas of China, and patients who
received HIV care at larger and more centralized health care
settings were more likely to be lost to care than patients receiving
care at village level clinics. In multivariable analyses the direction
of these relationships persisted although some were notably
attenuated, particularly the association between attrition and type
of health care setting.
Patients with higher CD4 cell counts at cART initiation were
more likely to be lost to care (Figure 2B). The hazard of attrition
among patients with CD4 cell counts greater than 350 cells/mL
was 1.6 times greater than for patients with CD4 cell counts less
than 50 cells/mL (HR=1.57; 95% CI:1.41, 1.74). The hazard of
attrition was relatively similar among patients with CD4 cell
counts less than 350 cells/mL at cART initiation. The relationship
between CD4 cell count and attrition persisted after multivariable
adjustment. For patients with CD4 cell counts greater than 350
cells/mL, the aHR was 1.76 (95% CI: 1.55, 2.00) (Table S2).
Patients with lower hemoglobin (HR=1.24; 95% CI: 1.12, 1.37)
and higher ALT (HR=1.28; 95% CI: 1.16, 1.41) were also more
likely to be lost, although ALT did not remain predictive in
multivariable analyses. Patients with more than four symptoms at
cART initiation had a higher hazard of attrition, even after
accounting for other characteristics.
Notably, attrition decreased with increasing cART initiation
calendar year (Figure 2C) and among patients who initiated
modern cART regimens (including 3TC with either NVP or EFV)
(Figure 2D). These relationships were consistent in multivariable
adjusted analyses (Table S2). To further assess the relationship
between calendar year of cART initiation and type of regimen
received, we compared cART regimens containing and not
containing lamivudine. We observed a persistent effect of
lamivudine associated with less attrition in models adjusting for
cART initiation calendar year and those stratified by cART
initiation calendar year (Table 1).
Figure 1. Cumulative probability of attrition among HIV-infected patients who initiated combination antiretroviral therapy in the
China National Free Antiretroviral Treatment Program, 2003–2010.
doi:10.1371/journal.pone.0039414.g001
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varying lengths of follow-up. We fit models to data where we
administratively censored follow-up at 12 and at 24 months
(Table 2). The reductions in attrition in more recent calendar
years persisted in all models and were comparable to results
observed relying on all patient observation time available. In
additional sensitivity analyses, using different time intervals to
define attrition, including 180, 270 and 360 days from last
observation, our results were consistent irrespective of the
definition of attrition we employed (data not shown). Finally we
evaluated the effect of excluding patients who were only seen once
by NFATP at their initial patient visit (n=2,896). Our results were
unaltered when we included this group of patients in our main
analyses (data not shown).
Discussion
At one year following cART initiation the cumulative proba-
bility of attrition was 9% and rose to 24% at 5 years among
patients receiving free antiretroviral therapy in China between
2003 and 2010 through the NFATP. This degree of retention in
care is slightly better than that observed in low-income areas of the
world (approximately 15% at one year) and slightly worse than
that observed in high-income areas of the world (approximately
5% at one year) [5]. In a recent study conducted in Uganda
attrition rates of 16%, 30% and 39% were observed at 1, 2 and 3
years following cART initiation, respectively [27].
Attrition was associated with both individual and contextual
factors. Consistent with prior studies patients who acquired HIV
through IDU were at substantial risk of being lost to care. In this
study 22% of patients accessing HIV care were IDU, in
comparison to 39% of HIV infections reported nationally [19].
This observation highlights that patients with IDU encounter
problems with both initiating and remaining in HIV care. In
contrast to previous studies where either CD4 cell counts did not
affect attrition or patients with lower CD4 cell counts had poorer
retention [7,29], among Chinese patients in NFATP we observed
greater attrition among patients with higher CD4 cell counts. This
result suggests that unrecognized mortality may not be a
substantial underlying cause of attrition in this study population.
However, attrition was higher among patients with lower
hemoglobin, which has been associated with greater mortality
[2,26].
We observed encouraging results that in more recent calendar
years and with the provision of newer cART regimens patients
were retained in care longer. In multivariable analyses we did not
observe substantial differences in attrition by type of clinic. Other
studies conducted in low-income settings have found a similar
attrition equality across large and small health care settings
[30,31,32].
Figure 2. Cumulative probability of attrition among HIV-infected patients who initiated combination antiretroviral therapy in the
China National Free Antiretroviral Treatment Program, 2003–2010; (A) by HIV exposure group; (B) by CD4 cell counts; (C) by
calendar year of therapy initiation; and (D) by type of initial regimen. Note: IDU =injection drug use; MSM=men who have sex with men;
blood = blood transfusion/former plasma donation; NVP=nevirapine; 3TC=lamivudine; AZT=zidovudine; D4T=stavudine; DDI=didanosine;
EFV=efavirenz.
doi:10.1371/journal.pone.0039414.g002
Table 1. Association between initial combination
antiretroviral regimen (Lamivudine/Non-lamivudine) and time
to attrition overall and stratified by calendar year of therapy
initiation.
HR (95% CI)
Unadjusted
Non-lamivudine 1.33 (1.25–1.41)
Lamivudine 1.00
Adjusted all factors but NOT calendar year{
Non-lamivudine 1.81 (1.65–1.98)
Lamivudine 1.00
Adjusted all factors and calendar year{
Non-lamivudine 1.39 (1.26–1.54)
Lamivudine 1.00
Adjusted stratified by calendar year of cART initiation*
2003–2004
Non-lamivudine N/A**
Lamivudine N/A**
2005–2006
Non-lamivudine 1.44 (1.24–1.67)
Lamivudine 1.00
2007–2008
Non-lamivudine 1.81 (1.55–2.11)
Lamivudine 1.00
2009–2010
Non-lamivudine 1.41 (0.97–2.07)
Lamivudine 1.00
Note: HR=hazard ratio; 95% CI=95% Confidence Interval; { Includes initial
regimen (lamivudine/Non-lamivudine) and patients’ age, gender, marriage
status, HIV exposure category, CD4 cell counts, hemoglobin level, clinical
symptoms, area of residence, health care setting but excludes the year of
starting therapy. { Includes all factors plus the year of starting therapy.
*Includes all factors but stratifies by the year of starting therapy.
**Because lamivudine was only available after 2005 in China; therefore we did
not make estimates during 2003–2004.
doi:10.1371/journal.pone.0039414.t001
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and the only study to date to be carried out in China. However
there are limitations to the present study. We were not able to link
the study population with death registries, nor was there active
follow-up of patients lost to care. Therefore, our estimate of
attrition includes patients who died but their death was not
reported to the clinic where they were receiving HIV care. In prior
studies conducted primarily in Africa as many as one-half of
patients not returning to HIV care were found to be deceased
when active tracing was available [33,34,35]. We do not know the
outcomes of patients lost to follow-up in NFATP; however, given
the relatively high CD4 cell counts among patients lost to care it is
possible that mortality may not have been a primary cause of
attrition from HIV care in this population. We were also unable to
evaluate the effect of longitudinal CD4 cell counts or HIV RNA
levels on retention as these data were not available in the early
years of the NFATP program. As additional information on these
biomarkers becomes available it will be important to evaluate how
they are associated with retention in HIV care. Additionally, given
the unique nature of the Chinese NFATP program our results may
not generalize to clinics in other areas of the world. For example,
as part of NFATP all patients received free antiretroviral therapy
as well as other needed HIV care. In other settings it has been
shown that retention increases in programs that offer free ART
[36]. We excluded patients with only one visit from our primary
analyses; however, including these patients did not affect our
results. We also treated deaths as a censoring event to be consistent
with prior literature [7]. It is possible that not treating death as a
competing risk may have resulted in some bias. Finally, we were
not able to take into account hepatitis B (HBV) co-infection among
HIV patients in this study. Although we were able to assess the
effect of ALT on retention this marker alone may not have
captured the entire effect of HBV co-infection, particularly given
the high prevalence of HBV in China [37] and its relationship to
greater mortality among HIV-infected patients [38].
These results have important implications for the management
of HIV in China. Treatment of HIV, even at higher CD4 cell
counts, clearly reduces transmission [17], and earlier treatment of
HIV has measurable improvement on patient outcomes [39]. But
these benefits can only be achieved if HIV infection is detected,
patients are efficiently referred for care, and following cART
initiation patients remain in active clinical follow-up. Any
substantial attrition, and certainly the level of attrition documented
in this study, can erode the benefits of antiviral therapy and give
rise to increased transmission of HIV and HIV drug resistance.
Reassuringly to date prevalence of transmitted HIV drug
resistance remains relatively low in China [40]. Our results
identify patients most likely to be lost, and several factors that help
to explain loss. These results must be used to design programs to
keep HIV-infected people in care, and over a very long period of
time.
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Table 2. Association between the calendar year of
combination antiretroviral therapy initiation and time to
attrition stratified by observation time.
HR (95% CI)
Follow-up time truncated at 12 months of follow-up:
Unadjusted
2003–2004 2.18 (1.92–2.48)
2005–2006 1.81 (1.68–1.96)
2007–2008 1.30 (1.22–1.39)
2009–2010 1.00
Adjusted all factors but NOT initial regimens{
2003–2004 4.28 (3.57–5.14)
2005–2006 1.77 (1.61–1.93)
2007–2008 1.20 (1.12–1.29)
2009–2010 1.00
Adjusted all factors and initial regimens{
2003–2004 4.08 (3.35–4.96)
2005–2006 1.85 (1.68–2.03)
2007–2008 1.23 (1.14–1.32)
2009–2010 1.00
Follow-up time truncated at 24 months of follow-up:
Unadjusted
2003–2004 2.23 (2.03–2.46)
2005–2006 1.74 (1.64–1.86)
2007–2008 1.29 (1.23–1.37)
2009–2010 1.00
Adjusted all factors but NOT initial regimens{
2003–2004 3.58 (3.09–4.16)
2005–2006 1.72 (1.60–1.85)
2007–2008 1.22 (1.15–1.30)
2009–2010 1.00
Adjusted all factors and initial regimens{
2003–2004 3.14 (2.67–3.69)
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of starting cART and patients’ age, gender, marriage status, HIV exposure
category, CD4 cell counts at enrollment, hemoglobin level, counts of baseline
symptoms, area of residence, health care setting and initial regimens but
excludes initial regimens. { Includes all factors plus initial regimens.
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